Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
Meta-analysis shows non-inferiority of later versus earlier immunotherapy administration in lung cancer
Chrono-immunotherapy may influence treatment outcomes, especially during the early phase of treatment, but its overall clinical impact remains to be clearly defined
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
RAS inhibition: a game changer in pancreatic cancer?
Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients
Cancer Research
Rethinking the immunotherapy paradigm for a sustainable and equal cancer care
Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access
Sex and gender are key for precision oncology and benefit all patients
Several misconceptions around sex- and gender-sensitive medicine still limit its application in cancer research and care
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
Next-generation PRAME-directed TCR T-cell therapy shows early activity in solid tumours
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial